Article Details

Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of ...

Retrieved on: 2024-10-29 20:33:20

Tags for this article:

Click the tags to see associated articles and topics

Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of .... View article details on hiswai:

Excerpt

SCORPIO-PEP is the First Phase 3 Trial with Post-Exposure Prophylactic Use of an Oral Antiviral to Meet the Primary Endpoint of Preventing ...

Article found on: www.shionogi.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo